This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC | MicrobiomeTrials
← Back to trials NCT06303505
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-06-12Est. Completion: 2027-12
Enrollment target: 250 participantsLocations The University of Alabama, Birmingham, Alabama, United States Yale Cancer Center, New Haven, Connecticut, United States Emory University, Atlanta, Georgia, United States Norton Cancer Institute Research, Louisville, Kentucky, United States Tufts, Boston, Massachusetts, United States Dana-Farber Cancer Institute, Boston, Massachusetts, United States START New Jersey East Brunswick, East Brunswick, New Jersey, United States Mount Sinai, New York, New York, United States Christ Hospital, Cincinnati, Ohio, United States Ohio State University, Columbus, Ohio, United States OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States Asante / Heimann Cancer Center, Medford, Oregon, United States Allegheny Singer, Pittsburgh, Pennsylvania, United States Spartanburg Regional, Spartanburg, South Carolina, United States Start Dfw, Fort Worth, Texas, United States Next Oncology Dallas, Irving, Texas, United States START Mountain Region, West Valley City, Utah, United States Other microbiome trials you might be interested in Advanced Solid Tumor Locally Advanced Solid Tumor Metastatic Solid Tumor Platinum-resistant Ovarian Cancer Post Anti-PD-1 Melanoma 2L+ Cervical Cancer Neoadjuvant Melanoma Neoadjuvant Non-Small Cell Lung Cancer Post Anti-PD-(L)1 Non-Small Cell Lung Cancer Post Anti-PD-(L)1 Small Cell Lung Cancer Third Line or Later (3L+) HER2+ Breast Cancer Second or Third Line (2L/3L) Cervical Cancer Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumor…
Inova Schar Cancer Institute, Fairfax, Virginia, United States
Next Oncology Virginia, Fairfax, Virginia, United States
Providence Sacred Heart Medical Center, Spokane, Washington, United States
UZ Leuven, Leuven, Belgium
Charité Universitätsmedizin Berlin, Berlin, Germany
University Hospital Cologne Department of Internal Medicine I, Cologne, Germany
Puerto Rico Cancer Clinical Trials, San Juan, Puerto Rico
Arensia Exploratory Medicine, Cluj-Napoca, Romania
Clínica universidad de Navarra, Madrid, Spain
NEXT Oncology Madrid, Madrid, Spain
Arensia Exploratory Medicine, Kyiv, Ukraine
Guy's Hospital, London, United Kingdom Los Angeles, United States Est. completion Aug 2027
Ovarian Cancer Fallopian Tube Cancers Primary Peritoneal Cancer High Grade Serous Adenocarcinoma of Ovary
The goal of this clinical trial is to learn how atorvastatin in patients with advanced high grade serous cancer of the o…
Aurora, United States Est. completion Aug 2028